2. Induced Disease Models Products Neuronal Signaling GPCR/G Protein Metabolic Enzyme/Protease
  3. Nervous System Disease Models Dopamine Receptor Endogenous Metabolite
  4. Parkinson's Disease Models
  5. L-DOPA

L-DOPA  (Synonyms: Levodopa; 3,4-Dihydroxyphenylalanine)

Cat. No.: HY-N0304 Purity: 99.98%
COA
SDS
Handling Instructions Technical Support

L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.

For research use only. We do not sell to patients.

CAS No. : 59-92-7

Size Price Stock Quantity
200 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 35 publication(s) in Google Scholar

Other Forms of L-DOPA:

L-DOPA Related Antibodies

Top Publications Citing Use of Products

35 Publications Citing Use of MCE L-DOPA

WB
In Vivo Efficacy Study
IHC

    L-DOPA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 13:e2413376.  [Abstract]

    Behavior analysis of pole test, rotarod test, suspension test, and forced swimming test after administration of L-DOPA, NanoMassage or saline. Mice were given an oral administration of 20 mg/kg L-DOPA on 4th day of MPTP administration and sacrificed on the 8th day.

    L-DOPA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 19:e2403058.  [Abstract]

    Movement track and total distance travelled in the open field test, descent time in the pole test and time-to-fall in the rotarod test. Mice in the treatment groups intragastrically (i.g.) administered 20 mg/kg/d L-DOPA for 27 days.

    L-DOPA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 19:e2403058.  [Abstract]

    Immunohistochemical staining of TH+ neurons. Mice in the treatment groups intragastrically (i.g.) administered 20 mg/kg/d L-DOPA for 27 days.

    L-DOPA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug 19:e2403058.  [Abstract]

    Quantification of TH+ neurons. Mice in the treatment groups intragastrically (i.g.) administered 20 mg/kg/d L-DOPA for 27 days.

    L-DOPA purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2023 Oct;29(10):2925-2939.  [Abstract]

    Amphiregulin (Areg) is highly expressed in the levodopa‐induced dyskinesia 6‐OHDA (4 μg; 4 weeks) Parkinson's disease mouse model. The Parkinson's disease group treated with a daily 12 mg/kg of levodopa for 15 days developed dyskinetic movement. On western blotting, this group further showed a significant increase of Amphiregulin protein expression relative to the Parkinson's disease group injected with normal saline only .

    View All Dopamine Receptor Isoform Specific Products:

    View All Isoforms
    Dopamine Receptor D1 Receptor D2 Receptor D3 Receptor D4 Receptor D5 Receptor

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

    IC50 & Target

    Human Endogenous Metabolite

     

    Cellular Effect
    Cell Line Type Value Description References
    CHO IC50
    141200 μM
    Compound: L-dopa
    TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells
    TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells
    		[PMID: 10052994]
    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    L-DOPA can be used to create movement disorder models. In adult common marmosets, after oral administration of L-DOPA (20 mg/kg, 5 mg/kg), the Tmax in plasma is 30 minutes, and the Tmax in striatal extracellular fluid (ECF) is 60-90 minutes. The mean Cmax of L-DOPA in plasma is 20.3 μM, while the mean Cmax in striatal ECF is 442.9 nM, representing about 2.2% of the plasma level[6].

    Induction of dyskinesia model[5]
    Background
    L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia[5].
    Specific Modeling Methods
    Mice: C57Bl/6 mice • male • 8 weeks (period: 21 days)
    Administration: 20 mg/kg • ip • once daily for 21 days
    Note
    (1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.
    (2) Injection volume is 10mL/kg body weight.
    Modeling Indicators
    Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion.
    Correlated Product(s): Oxidopamine hydrochloride (HY-B1081)
    Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 7-week-old C57BL/6J mice[3]
    Dosage: 20 mg/kg
    Administration: Orally
    Result: Reduced Rotenone-induced motor dysfunction.
    Animal Model: Sprague-Dawley rats (male 100-150 g)[4]
    Dosage: 10, 30, 50, 70, and 100 mg/kg
    Administration: Orally
    Result: Reverses tactile, cold and heat allodynia in neuropathic rat without any side effect.
    Molecular Weight

    197.19

    Formula

    C9H11NO4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    N[C@@H](CC1=CC(O)=C(C=C1)O)C(O)=O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, stored under nitrogen

    *The compound is unstable in solutions, freshly prepared is recommended.

    Solvent & Solubility
    In Vitro: 

    0.1 M HCl : 20 mg/mL (101.43 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)

    DMSO : 2 mg/mL (10.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 1 mg/mL (5.07 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.0713 mL 25.3563 mL 50.7125 mL
    5 mM 1.0143 mL 5.0713 mL 10.1425 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 3.33 mg/mL (16.89 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.98%

    SDS (393 KB)

    COA (246 KB) RP-HPLC (230 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO / 0.1 M HCl 1 mM 5.0713 mL 25.3563 mL 50.7125 mL 126.7813 mL
    5 mM 1.0143 mL 5.0713 mL 10.1425 mL 25.3563 mL
    DMSO / 0.1 M HCl 10 mM 0.5071 mL 2.5356 mL 5.0713 mL 12.6781 mL
    0.1 M HCl 15 mM 0.3381 mL 1.6904 mL 3.3808 mL 8.4521 mL
    20 mM 0.2536 mL 1.2678 mL 2.5356 mL 6.3391 mL
    25 mM 0.2029 mL 1.0143 mL 2.0285 mL 5.0713 mL
    30 mM 0.1690 mL 0.8452 mL 1.6904 mL 4.2260 mL
    40 mM 0.1268 mL 0.6339 mL 1.2678 mL 3.1695 mL
    50 mM 0.1014 mL 0.5071 mL 1.0143 mL 2.5356 mL
    60 mM 0.0845 mL 0.4226 mL 0.8452 mL 2.1130 mL
    80 mM 0.0634 mL 0.3170 mL 0.6339 mL 1.5848 mL
    100 mM 0.0507 mL 0.2536 mL 0.5071 mL 1.2678 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    L-DOPA Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    L-DOPA59-92-7Levodopa 3,4-DihydroxyphenylalanineDopamine ReceptorEndogenous MetaboliteOrallyprecursorneurotransmittersdopamineblood-brainbarrieranti-allodynicParkinsonInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    L-DOPA
    Cat. No.:
    HY-N0304
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.